HCA three-lens brief

Evidence-based stock research on HCA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.

Get full HCA research How the three lenses work

52-week rangeas of Jul 10

$330.00$402.97$556.52

Performance

-1.8%

+6.8%

-18.7%

-14.6%

YTD

-13.7%

+6.5%

—

HCA · Nightly brief

Watch

Analyst mean target $493.52 — 22% above current (21 analysts).

Analyst mean target $493.52 — 22% above current (21 analysts).
Earnings scheduled 2026-07-24.

HCA closed at $402.97 (-1.47%) as of 2026-07-10. Market cap: $89.39B. P/E (trailing) 13.9. Price is above the 50-day MA and below the 200-day MA. Positives: analyst mean target $493.52 — 22% above current (21 analysts).. Last quarter: Revenue $19.11B, net income $1.62B, free cash flow $5.73B. Watching for: 2026-07-24 earnings release (13 days out).

Market ✓· Fundamentals ✓· 1 events

Informational only · Not investment advice

Three-lens method

Why three lenses on HCA, not one.

A single reasoning model has blind spots it doesn’t know about. We examine HCAacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.

Read the full methodology

Embed this brief

Drop it in your newsletter or blog.

Free to embed. Updates every 6 hours. Links back to the full brief.

<iframe
  src="https://clearpathinvest.app/embed/HCA"
  width="100%" height="420" frameborder="0"
  loading="lazy"
  title="ClearPath HCA brief"></iframe>

Also on ClearPath

Methodology

The five-stage pipeline

Compare

ClearPath vs. big dashboards

Transparency

Public track record